Cargando…
A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals
Background: SARS-CoV-2 is a coronavirus that has rapidly spread across the world with a detrimental effect on the global population. Several reports have highlighted an increased mortality rate and a higher severity of COVID-19 infection in chronic kidney disease (CKD) individuals. Upon the developm...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732501/ https://www.ncbi.nlm.nih.gov/pubmed/36531259 http://dx.doi.org/10.12688/f1000research.122820.2 |
_version_ | 1784846149229740032 |
---|---|
author | Malik, Soniya A. Modarage, Kavindiya Goggolidou, Paraskevi |
author_facet | Malik, Soniya A. Modarage, Kavindiya Goggolidou, Paraskevi |
author_sort | Malik, Soniya A. |
collection | PubMed |
description | Background: SARS-CoV-2 is a coronavirus that has rapidly spread across the world with a detrimental effect on the global population. Several reports have highlighted an increased mortality rate and a higher severity of COVID-19 infection in chronic kidney disease (CKD) individuals. Upon the development of various SARS-CoV-2 vaccines, mRNA vaccines including BNT162b2 and mRNA-1273 were deemed safe, with a high efficacy in preventing COVID-19 in the general population. This review investigates whether SARS-CoV-2 mRNA vaccines are as effective in triggering an immune response in Dialysis Patients (DPs) and Kidney Transplant Recipients (KTRs) and if a third dose is required in this population. Methods: A systematic search employing the PRISMA criteria was conducted in several major databases, with the data being extracted from publications for the period January 2021 to May 2022 (PROSPERO: CRD42022338514, June 15, 2022). Results: 80 studies were included in this analysis with a total cohort number of 15,059 participants. Overall, 85.29% (OR = 17.08, 95% CI = 15.84-18.42, I (2) = 98%) and 41.06% (OR = 0.52, 95% CI = 0.48-0.5, I (2) = 95%) of DPs and KTRs included in this review showed positive seroconversion after two doses of either mRNA vaccine, respectively. A total 76% (OR = 6.53, 95% CI = 5.63-7.5, I (2) = 96%) of the cohort given a third dose of an mRNA vaccine demonstrated positive seroconversion, with 61.86% (OR = 2.31, 95% CI = 1.95-2.75 I (2) = 95%) of the cohort that was assessed for a cellular response displaying a positive response. Conclusions: This data emphasises a reduced incidence of a positive immune response in DPs and KTRs compared to healthy controls, albeit a better response in DPs than when compared to KTRs alone was observed. A third dose appears to increase the occurrence of an immune response in the overall DP/KTR cohort. |
format | Online Article Text |
id | pubmed-9732501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-97325012022-12-15 A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals Malik, Soniya A. Modarage, Kavindiya Goggolidou, Paraskevi F1000Res Systematic Review Background: SARS-CoV-2 is a coronavirus that has rapidly spread across the world with a detrimental effect on the global population. Several reports have highlighted an increased mortality rate and a higher severity of COVID-19 infection in chronic kidney disease (CKD) individuals. Upon the development of various SARS-CoV-2 vaccines, mRNA vaccines including BNT162b2 and mRNA-1273 were deemed safe, with a high efficacy in preventing COVID-19 in the general population. This review investigates whether SARS-CoV-2 mRNA vaccines are as effective in triggering an immune response in Dialysis Patients (DPs) and Kidney Transplant Recipients (KTRs) and if a third dose is required in this population. Methods: A systematic search employing the PRISMA criteria was conducted in several major databases, with the data being extracted from publications for the period January 2021 to May 2022 (PROSPERO: CRD42022338514, June 15, 2022). Results: 80 studies were included in this analysis with a total cohort number of 15,059 participants. Overall, 85.29% (OR = 17.08, 95% CI = 15.84-18.42, I (2) = 98%) and 41.06% (OR = 0.52, 95% CI = 0.48-0.5, I (2) = 95%) of DPs and KTRs included in this review showed positive seroconversion after two doses of either mRNA vaccine, respectively. A total 76% (OR = 6.53, 95% CI = 5.63-7.5, I (2) = 96%) of the cohort given a third dose of an mRNA vaccine demonstrated positive seroconversion, with 61.86% (OR = 2.31, 95% CI = 1.95-2.75 I (2) = 95%) of the cohort that was assessed for a cellular response displaying a positive response. Conclusions: This data emphasises a reduced incidence of a positive immune response in DPs and KTRs compared to healthy controls, albeit a better response in DPs than when compared to KTRs alone was observed. A third dose appears to increase the occurrence of an immune response in the overall DP/KTR cohort. F1000 Research Limited 2022-11-22 /pmc/articles/PMC9732501/ /pubmed/36531259 http://dx.doi.org/10.12688/f1000research.122820.2 Text en Copyright: © 2022 Malik SA et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Systematic Review Malik, Soniya A. Modarage, Kavindiya Goggolidou, Paraskevi A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title | A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title_full | A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title_fullStr | A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title_full_unstemmed | A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title_short | A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals |
title_sort | systematic review assessing the effectiveness of covid-19 mrna vaccines in chronic kidney disease (ckd) individuals |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732501/ https://www.ncbi.nlm.nih.gov/pubmed/36531259 http://dx.doi.org/10.12688/f1000research.122820.2 |
work_keys_str_mv | AT maliksoniyaa asystematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals AT modaragekavindiya asystematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals AT goggolidouparaskevi asystematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals AT maliksoniyaa systematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals AT modaragekavindiya systematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals AT goggolidouparaskevi systematicreviewassessingtheeffectivenessofcovid19mrnavaccinesinchronickidneydiseaseckdindividuals |